Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia
| Autor: | Elisabeth Kapaki, Ioannis Evdokimidis, Evie Kourtidou, Anastasia Bougea, Dimitrios Kasselimis, Vasilios C. Constantinides, C. Potagas, George P. Paraskevas |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male Pathology medicine.medical_specialty Enzyme-Linked Immunosorbent Assay tau Proteins Disease Primary progressive aphasia 03 medical and health sciences 0302 clinical medicine Cerebrospinal fluid mental disorders medicine Humans Phosphorylation Aged Aged 80 and over Amyloid beta-Peptides business.industry General Neuroscience General Medicine Frontotemporal lobar degeneration respiratory system Middle Aged medicine.disease Pathophysiology Peptide Fragments Psychiatry and Mental health Clinical Psychology 030104 developmental biology Aphasia Primary Progressive ROC Curve Csf biomarkers Etiology Biomarker (medicine) Female Geriatrics and Gerontology business 030217 neurology & neurosurgery Biomarkers |
| Zdroj: | Journal of Alzheimer's disease : JAD. 55(4) |
| ISSN: | 1875-8908 |
| Popis: | Background Primary progressive aphasia (PPA) may present with three main clinical variants, namely nonfluent agrammatic (nfaPPA), semantic (sPPA), and logopenic (lPPA) subtypes. Frontotemporal lobar degenerations (FTLD) or Alzheimer's disease (AD) are the most common etiologies. Objective To study the potential of cerebrospinal fluid (CSF) biomarkers for identifying the underlying pathology in patients with PPA. Methods CSF levels of total tau protein (τT), amyloid-β peptide (Aβ42), and tau phosphorylated at threonine-181 (τP - 181) were measured by double sandwich, enzyme-linked immunosorbent assay (ELISA) in 43 patients with PPA, 26 patients with AD, and 17 healthy controls. Results All patients could be classified as compatible with the AD or non-AD biomarker profile, either with the three biomarkers (90.7%) or their ratios, especially the τP - 181/Aβ42 ratio (9.3%). An AD-compatible biomarker profile was present in 39.5% of all PPA patients, specifically 22.2%, 35.7%, and 75% of nfaPPA, sPPA, and lPPA, respectively. In PPA patients with a non-AD profile (presumably FTLD), two different clusters could be identified according to the τP - 181/τT ratio, possibly corresponding to the two major FTLD pathologies (tau and TDP-43). Conclusion CSF biomarkers may be a valuable tool for the discrimination between PPA patients with AD and non-AD pathophysiology and possibly between FTLD patients with tau and TDP-43 pathology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|